The legendary billionaire macro trader, Stanley Druckenmiller, has built his career on a simple habit. When he finds a bet he believes in, he sizes it big and watches it closely.

Right now, that bet is a cancer-testing company most people have never heard of: Natera (NTRA), and the reason he keeps buying tells you something useful about where he thinks healthcare is going.

His family office holds more of it than any other stock, and he added to the position last quarter even as the shares traded near record highs.

What Druckenmiller's Natera bet actually looks like right now

Druckenmiller runs his money through the Duquesne Family Office, and his stock holdings show up every quarter in a public filing called a 13F.

A 13F is a report that large investors must file with the Securities and Exchange Commission, listing the U.S. stocks they own.

His most recent filing, dated August 14, 2026, covers the second quarter and shows Natera as his single largest holding at 16.6% of the reported portfolio, according to the SEC filing.

More Healthcare Stocks:

• Federal court hands Gilead a win that protects its top HIV drug

• BofA biotech scorecard: Two buys and odd one out

• Lilly gains access to market that could add millions of customers

That's worth about $864.9 million.

He did not just hold the position. He added 122,700 shares during the quarter, lifting the stake to about 3.19 million shares.

That detail matters, because the stock was expensive at the time. He kept buying anyway.

Why a macro trader put so much into one healthcare stock

Druckenmiller made his name betting on currencies, interest rates, and big economic shifts, not on individual biotech companies.

So a concentrated Natera position looks unusual on the surface.

The logic becomes clearer when you look at what Natera sells. 

Its main product is Signatera, a blood test that looks for tiny fragments of tumor DNA left in the body after cancer treatment.

Doctors use it to catch a cancer coming back earlier than a scan would show.

That is a service hospitals order regardless of the economy. A patient monitored for cancer recurrence gets tested whether interest rates rise or fall.

For an investor who spends his days worrying about the economy, a business that keeps selling through a downturn is rare.

How Natera's latest results support the thesis

The numbers behind the bet are strong.

Natera reported second-quarter revenue of $752.8 million on August 6, 2026, up 37.7% from a year earlier.

That beat Wall Street's estimate of about $662.6 million.